The kallistatin level is modified in various pathologies, ranging from liver cirrhosis to cancer and obesity, and it has some protective effects against pathological conditions (e.g., hypertension, cardiovascular damage), as demonstrated by its administration by gene/protein delivery in animal models [55]. The gene discussed is SERPINA4; the disease is cirrhosis of liver.